Observational trial showed greater fat-free and muscle mass gains in children on Dolutegravir than on other treatments, indicating potential metabolic implications of fat accrual.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Nambi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: